Predict your next investment

Corporate Venture
fletcherspaght.com/ventures

See what CB Insights has to offer

Investments

68

Portfolio Exits

16

Funds

2

About Fletcher Spaght Ventures

Fletcher Spaght Ventures, (FSV) is a balanced-stage venture capital firm investing in high growth opportunities in healthcare/life sciences and related information technology companies. FSV was established in 2001 by Fletcher Spaght (FSI), a strategy consulting firm founded in 1983. FSV's healthcare/life science interests include: medical devices, diagnostics, research and development tools, biotechnology, regenerative medicine, healthcare services, and data management solutions and analytics to transform processes, reduce costs and/or improve outcomes.

Fletcher Spaght Ventures Headquarter Location

222 Berkeley Street 20th Floor

Boston, Massachusetts, 02116,

United States

617-247-6700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Fletcher Spaght Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Fletcher Spaght Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Fletcher Spaght Ventures News

Cellanyx Announces Appointment of Guy Fish, MD, MBA to its Leadership Team

Feb 25, 2019

February 25, 2019 09:30 AM Eastern Standard Time BEVERLY, Mass.--( BUSINESS WIRE )--Cellanyx announced today that it has appointed Guy Fish, MD, MBA, as a member of its Board and as acting CEO, effective immediately. Dr. Fish joins Cellanyx after more than a 30-year career in the health care industry, most recently at the healthcare technology strategy firm, Fletcher Spaght, where he was Senior Vice President, and he also served as the Vice President of its venture arm, Fletcher Spaght Ventures. Ashok Chander, PhD, Cellanyx’s co-founder, technology inventor and former CEO, will become Chief Technology Officer. “Guy brings an enormous breadth of experience in clinical practice as well as healthcare strategy that spans new technology assessment, business development, fund raising and commercialization for emerging biotechnology companies,” said Pravin Chaturvedi, PhD, Chairman of the Cellanyx board of directors. “Cellanyx is at a key point in the development of its first-in-class live tumor cell phenotypic testing platform and of its lead risk stratification test for prostate cancer. Guy is the ideal candidate to spearhead the efforts to commercialize our prostate risk-stratification test and to accelerate the development of other cancer phenotypic tests.” “Cellanyx has developed a powerful, first-in-class oncology phenotypic biomarker platform that combines two of the most exciting technologies in medical science: single cell analysis and machine learning/AI. Phenotypic analysis of live cells from biopsies has transformative potential to modernize cancer pathology from the 150-year old analysis of morphology and artifacts to clear observation of cell behaviors of aggressiveness and metastatic potential,” said Dr. Fish. “The recent publications of Cellanyx’s core technology in Nature Biomedical Engineering and clinical proof-of-concept study for the company’s prostate test in Urology, underscore the promise of its approach. I look forward to working with the team to advance this promising technology with the goal of improving clinical decision making and patient care.” Prior to Fletcher Spaght, Dr. Fish served as Vice President of Business Development at Collagenesis Inc. Prior to that he was a medical device Equities Analyst at Sanford Bernstein, and previously was a Senior Consultant at the Boston Consulting Group. Dr. Fish has served on many corporate and non-profit boards. He currently serves as a Trustee of Beth Israel Deaconess Medical Center, the Altarum Institute, and the Hydrocephalus Association. Dr. Fish received his MD from the Yale University School of Medicine and completed his residency at Case Western. He received his MBA from the Yale School of Management. He also holds a Bachelor’s Degree in Biochemistry from Harvard University. About Cellanyx Cellanyx is developing a first-in-class live tumor cell, phenotypic platform for precision risk stratification in cancer to help clinical treatment decision making. The company’s platform directly assesses the dynamic behavior of thousands of live tumor cells and their phenotypic biomarkers and quantifies the hallmarks of cancer and cancer aggressiveness such as cell movement and protein dynamics. Big data and machine vision learning techniques are utilized to select biomarkers that predict adverse pathology at the time of surgery. The company’s lead test, for prostate cancer, has demonstrated clinical proof of concept in a study of more than 300 tissue samples from radical prostatectomy patients. Learn more at www.cellanyx.com .

Fletcher Spaght Ventures Investments

68 Investments

Fletcher Spaght Ventures has made 68 investments. Their latest investment was in Metabolon as part of their Unattributed VC on September 9, 2020.

CBI Logo

Fletcher Spaght Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/11/2020

Unattributed VC

Metabolon

$21.77M

No

2

11/13/2018

Series E

Swift Biosciences

$4M

No

1

9/5/2018

Series D

PhaseBio Pharmaceuticals

$34M

No

4

8/15/2018

Series E - IV

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2017

Convertible Note - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/11/2020

11/13/2018

9/5/2018

8/15/2018

11/29/2017

Round

Unattributed VC

Series E

Series D

Series E - IV

Convertible Note - II

Company

Metabolon

Swift Biosciences

PhaseBio Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$21.77M

$4M

$34M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

4

10

10

Fletcher Spaght Ventures Portfolio Exits

16 Portfolio Exits

Fletcher Spaght Ventures has 16 portfolio exits. Their latest portfolio exit was Swift Biosciences on March 11, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/11/2021

Acquired

5

8/19/2020

Asset Sale

1

9/10/2019

Acquired

$991

4

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/11/2021

8/19/2020

9/10/2019

00/00/0000

00/00/0000

Exit

Acquired

Asset Sale

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

1

4

10

10

Fletcher Spaght Ventures Fund History

2 Fund Histories

Fletcher Spaght Ventures has 2 funds, including Fletcher Spaght Ventures II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2008

Fletcher Spaght Ventures II LP

Multi-Stage Venture Capital

$50M

1

12/31/2001

Fletcher Spaght Ventures LP

Subscribe to see more

$99M

10

Closing Date

12/31/2008

12/31/2001

Fund

Fletcher Spaght Ventures II LP

Fletcher Spaght Ventures LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Amount

$50M

$99M

Sources

1

10

Fletcher Spaght Ventures Team

3 Team Members

Fletcher Spaght Ventures has 3 team members, including current President, Peary Spaght.

Name

Work History

Title

Status

Kinney L. Johnson

Founder

Current

Peary Spaght

President

Current

Martin Inglis

Chief Financial Officer

Current

Name

Kinney L. Johnson

Peary Spaght

Martin Inglis

Work History

Title

Founder

President

Chief Financial Officer

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.